Hikma Confirms Strategy, Guidance
Hikma Pharmaceuticals maintains strategic execution and reaffirms guidance.
ASH 2024: Astrazeneca Showcases Haematology Advancements o Transform Cancer Care
AstraZeneca highlights its hematology portfolio and pipeline at ASH 2024.
Givaudan Ceo Gilles Andrier Won The CEW Achiever Award
Givaudan CEO Gilles Andrier received the CEW Achiever Award of Honour, recognizing his contribution to the beauty industry and commitment to CEW Beauty…
Lenzing’s Revenue Up 5%; Confirms 2024 EBITA Guidance Despite High Costs
Lenzing Group's revenue rose 5% to EUR 2 bn in early 2024, with EBITDA up 20.3% to EUR 263.7 mn and free cash…
Munich Re Expects To Exceed €5Bn Annual Target
Munich Re's Q3 2024 financial results show a net profit of €930m, with an annual target expected to be surpassed.
Rheinmetall Sales +33%, Earnings +70%.
Rheinmetall reports record sales increase of over 30% and earnings rise by over 70%.
Swiss Re 2024 Net Income To Exceed $3B
Swiss Re increased US liability reserves by $2.4 billion in Q3 2024 after a comprehensive review, aiming for reserves at the higher end…
Qiagen’s Q3 2024 Sales Rose 5% To $502M
QIAGEN reports strong growth in Q3 2024, exceeding expectations. Net sales reached $502 million with a 6% increase in constant exchange rates.
更新：阿斯利康如有需要将配合中国调查
阿斯利康股价在过去五天内下跌近10%，原因涉及其在中国的业务。如今，该公司在简短声明中回应了有关中国正在进行调查的媒体报道。
Update: Rheinmetall Restructures Executive Board, Eyes €20 Billion Annual Sales Goal
Rheinmetall Executive Board reorganized for growth.